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In men aged less than 60, the association of serum and urinary levels of biochemical bone turnover markers (BTMs) and bone
mineral density (BMD) is weak or not signiﬁcant. After this age, higher BTM levels are correlated weakly, but signiﬁcantly, with
lowerBMDandfasterboneloss.LimiteddatafromthecohortstudiessuggestthatBTMmeasurementdoesnotimprovethepredic-
tion of fragility fractures in older men in comparison with age, BMD, history of falls and fragility fractures. Testosterone replace-
ment therapy (TRT) decreases bone resorption. During TRT, bone formation markers slightly increase (direct eﬀect on osteo-
blasts), then decrease (slowdown of bone turnover). Bisphosphonates (alendronate, risedronate, ibandronate, zoledronate) induce
a rapid decrease in bone resorption followed by a milder decrease in bone formation. In men receiving antiresorptive therapy
for prostate cancer, zoledronate, denosumab and toremifene decrease signiﬁcantly levels of bone resorption and bone formation
markers. Teriparatide induced a rapid increase in serum concentrations of bone formation markers followed by an increase in
bone resorption. We need more studies on the utility of BTM measurement for the improvement of the persistence and adherence
to the anti-osteoporotic treatment in men.
1.Introduction
Biochemical markers of bone turnover (BTMs) have been
investigated in several male cohorts for the last 15 years.
These studies provided data on age-related changes in bone
turnover rate in men and on potential determinants of bone
turnover rate in men, such as hormones, lifestyle factors, dis-
eases,ormedications.However,dataonpracticaluseofBTM
in the clinical management of osteoporosis in men are limit-
ed and rather disappointing.
There are two groups of biochemical bone turnover
markers (BTMs), markers of bone formation and markers
of bone resorption (Table 1). OC, PICP, and PINP are re-
leased during the synthesis of OC and type I collagen which
are constituents of bone matrix. CTX-I, NTX-I, PDP, and
PYD are products of catabolism of type I collagen [1]. Bone
APandTRACP5bareenzymesreﬂectingthemetabolicactiv-
ity, respectively, of osteoblasts and osteoclasts. Recently, it
has been proposed that PINP and serum CTX-I become




The association between BTM levels and areal bone mineral
density(aBMD)measuredbydualenergyX-rayabsorptiom-
etry (DXA) was assessed in cross-sectional studies. Before
the age of 60, the association was nonsigniﬁcant [3]. It may
reﬂect two processes. In young adult men, the consolidation,
that is, formation of peak aBMD after the growth arrest,
is associated with a slowdown of bone turnover. However,
one BTM level cannot reﬂect diﬀerent trends which vary
according to the skeletal site. In middle-aged men, apparent
stabilityofaBMDisatrade-oﬀbetweenperiostealapposition
and endosteal bone loss. As these processes are slow, aBMD
may depend more on the peak aBMD acquired previously
than on the current bone turnover rate.
After the age of 60, BTM levels were correlated moder-
ately negatively with aBMD [3, 4]. The diﬀerence in average
aBMD between the lowest and the highest BTM quartiles
varied from 3 to 12%. Prospective data on the association
between BTM levels and bone loss in men are scanty and,2 Journal of Osteoporosis
Table 1: Biochemical bone turnover markers.
Bone formation
Osteocalcin (OC)
Bone alkaline phosphatase (bone ALP)
N-terminal propeptides of type I procollagen (PINP)
C-terminal propeptides of type I procollagen (PICP)
Bone resorption
C-terminal cross-linking telopeptides of type I collagen
(CTX-I),
N-terminal cross-linking telopeptides of type I collagen
(NTX-I)
C-terminal cross-linking telopeptide of type I collagen
generated by matrix metalloproteinases (CTX-MMP, ICTP)
Helical peptide 620–633 of the a1 chain
Deoxypyridinoline (DPD)
Pyridinoline (PYD)
Isoform 5b of tartrate resistant acid phosphatase (TRACP5b)
most often, negative. Higher BTM levels were associated
with faster bone loss at some skeletal sites (e.g., hip, distal
forearm), but not all (e.g., spine) [5–7].
Several factors can contribute to these results. Bone loss
is slower in men than n women, especially before the age of
70. Thus, a long-term follow-up is necessary to obtain an
accurate estimate of bone loss. The rate of bone loss may
vary according to the skeletal site. In particular, lumbar spine
is not a reliable skeletal site for estimation of bone loss in
men because of frequent osteoarthritis. The assessment of
bone loss (which is in fact the endosteal bone loss) is biased
by the concomitant periosteal apposition. This process is
present in both older men and women; however, it may have
a greater impact in men who have lower endosteal bone loss
and greater periosteal apposition than in women. Finally,
bone turnover is inﬂuenced by many factors and a single
measurement of BTM may not correspond to the average
bone turnover rate over a long period of time.
3.AssociationbetweenBTMLevelsandtheRisk
of Fracture in Men
Several prospective cohort and case-control studies showed
thatelevatedBTMlevelspredictfracturesinpostmenopausal
women after adjustment for age, aBMD, and history of
fracture. This association was found mainly in follow-ups
lasting <5 years, mainly for bone resorption markers, and
mainly for major osteoporotic fracture (mainly hip fracture)
[1, 7]. Fewer studies concerned the prediction of fractures by
BTM in men. The cohort studies (MrOS, MINOS) showed
that, in older men, higher BTM levels did not predict
fractures in models adjusted for age and aBMD [5, 6].
Two studies suggested that BTMs predict fractures in men.
However, the association between low gammacarboxylation
of osteocalcin (OC) and fracture risk was not adjusted for
aBMD [8]. In the Dubbo cohort, only C-terminal cross-
linking telopeptide of type I collagen generated by metal-
loproteinase (ICTP), but not other BTM, was predictive of
fracture [9]. In addition, some methodological limitations
should be recognized (lack of standardization of blood
collection, suboptimal ascertainment of incident fractures).
In a more recent study in the MrOS cohort, higher levels
of urine alpha CTX isomer/Cr and greater alpha/beta CTX
isomer ratio were associated with a higher risk of clinical
vertebral fracture [10].
The reason for the diﬀerence between men and women
is not clear. The higher bone turnover results in the
deterioration of bone strength through several mechanisms:
fasterboneloss,increasedformationofstressrisers,impaired
trabecularconnectivity,higherfractionofbonewhichisonly
partly mineralized, and greater fraction of protein matrix
which has undergone posttranslational modiﬁcations only
partly. However, the “elevated” BTM levels (e.g., the highest
sex-speciﬁc quartile) correspond to higher absolute BTM
levels and faster bone turnover in women than men. Thus,
the loss of bone strength due to faster bone turnover may
be less in men than in women. In addition, in men, this
smaller decline in bone strength occurs in bones which are
larger and stronger. Thus, the loss of bone strength due to
the faster bone turnover may have a smaller impact on the
o v e r a l lf r a c t u r er i s ki nm e nt h a ni nw o m e n .
4. Limitations and Potential Interest of BTM in
the ClinicalPractice
Analytical and preanalytical variability have a strong eﬀect
on the BTM levels. The analytical variability depends on
the BTM, the measurement method, and the technician’s
expertise.
Thepreanalyticalvariabilitycomprisesmanyfactors.Cir-
cadian rhythm has a strong impact on the BTM variability,
mainly serum bone resorption markers (CTX-I) [11]. Bone
turnover is inﬂuenced by the vitamin D and calcium status,
mainly in the elderly. BTM levels are increased especially in
the institutionalized and home-bound vitamin D-deﬁcient
elderly who have secondary hyperparathyroidism associated
with markedly increased BTM levels [12]. The seasonal
variation of sunlight exposure leads to lower vitamin D level
in winter. Consequently, levels of parathyroid hormone and
BTM are higher in winter, mainly in the elderly.
Furthermore, BTM levels are inﬂuenced by a recent
fracture, especially during the ﬁrst 4 months [13]. GnRH
agonists (used in the treatment of prostate cancer) inhibit
the androgen secretion and decrease the 17β-œstradiol level
leading thereby to a higher bone turnover and bone loss.
In some clinical situations, BTM levels may help to
establishdiagnosis.Forinstance,BTMsareelevatedinhyper-
thyroidism, primary hyperparathyroidism, or Paget’s disease
[1]. By contrast, BTMs are decreased in hypothyroidism,
hypoparathyroidism, or hypopituitarism. BTM levels are
usually increased in patients with bone metastases and their
levels are correlated with the spread of bone metastases [14].
A particular situation is multiple myeloma characterized
by low OC concentration and markedly increased bone
resorption.
Endogenous and exogenous corticosteroids inhibit bone
formation [15]. The decrease in OC level is rapid andJournal of Osteoporosis 3
followed by a delayed and milder decrease in PICP and PINP.
Bone resorption can increase transiently. Inhaled corticos-
teroids decrease OC levels in a dose- and drug-dependent
manner without signiﬁcant eﬀect on other BTMs [16].
5. Effect of Antiosteoporotic Treatment on
BTM in Men
5.1. Testosterone Replacement Therapy (TRT). In most, but
not all, studies, TRT decreased bone resorption marker levels
[17–21]. However, decrease in the urinary excretion of bone
resorptionmarkerspermgurinarycreatinineispartlyrelated
to the increase in muscle mass, and this result should be
interpreted cautiously. Bone formation markers (especially
osteocalcin and N-terminal type I collagen propeptide
(P1NP)) increase slightly during the ﬁrst weeks of TRT [18,
20]. This increase may reﬂect the direct stimulatory eﬀect
of TRT on osteoblasts in preexisting bone remodeling units.
Later on, bone formation markers decrease, what reﬂects the
g e n e r a ls l o w d o w ni nb o n et u r n o v e r[ 20, 21]. However, this
trend has not been found consistently [19].
Overall, data on the eﬀect of TRT on BTM levels are dis-
cordant. The eﬀect of TRT on bone turnover in hypogonadal
men depends on factors such as the initial hormonal status
(severity and duration of hypogonadism, hypogonadism
developed in childhood or in adult age, and isolated hypog-
onadism or multihormonal deﬁcit), baseline bone turnover
rate, intramuscular or transdermal route of TRT adminis-
tration, and normalization of testosterone level during treat-
mentandtreatmentduration[22].Testosteroneincreasesthe
collagen synthesis in other tissues (e.g., muscles), which is
conﬁrmed by an increase in the serum level of N-terminal
propeptide of type III collagen [23]. Thus, the potential
contribution of muscle collagen to the circulating PINP
and PICP levels is possible. Methodological limitations of
certain studies should be recognized (small heterogeneous
groups, lack of control group, large dropout, various doses
of testosterone analyzed jointly, and impossibility to assess
adherence to treatment).
5.2. Antiresorptive Treatment. Bisphosphonates are potent
inhibitors of bone resorption. The studies in men concern
mainly alendronate, risedronate, ibandronate, and zole-
dronate. After a given type of bisphosphonate, changes in
BTM levels were similar in various groups of men with
primary and secondary osteoporosis. Alendronate (10mg
daily per os) decreased bone resorption marker levels by
about 50% after 3 months of treatment, what was followed
by a milder (30 to 40%) decrease in the serum levels of bone
formation markers [24–26]. Similar trends were observed
in men with primary or secondary osteoporosis related to
hypogonadism or corticotherapy.
Risedronate (2.5 or 5mg daily or 35mg weekly per os)
decreased bone resorption markers by 40 to 50% after 3
months of treatment, what was followed by a milder (25–
30%) decrease in serum levels of bone formation markers.
Similar trends were observed in osteoporotic men aged 30
and over, older Japanese men with untreated osteoporosis,
men on corticosteroid therapy, elderly men after stroke and
elderly men with Parkinson’s disease [27–31].
In 14 patients with Klinefelter’s syndrome, intravenous
ibandronate (2mg every 3 months) decreased urinary levels
of bone resorption markers by 30 to 70% after one month
[32]. This decrease was followed by a milder decrease (25–
35%) in bone formation markers. In men with low aBMD
(STRONG study), once-monthly oral ibandronate (150mg)
induced a 40 to 50% decrease in serum concentration of C-
terminaltelopeptideoftypeIcollagen(CTX-I)accompanied
by a 20–30% decrease in bone alkaline phosphatase (BAP)
activity [33].
BTMs were assessed in several studies carried out in men
treated with zoledronate (5mg i.v. once yearly in men with
primary osteoporosis or hypogonadism, 4mg i.v. once yearly
in HIV-infected men with low aBMD, single dose i.v. 4mgin
osteopenic cancer survivors) [34–36]. Zoledronate induced
ap r o f o u n dd e c r e a s e( >60%) in bone resorption markers
within the ﬁrst week of treatment followed by a milder (30–
40%) decrease in bone formation markers.
Finally, antiresorptive medications were assessed in men
receiving androgen-deprivation therapy for prostate can-
cer. In this group, zoledronate, denosumab (monoclonal
anti-RANKL antibody), and toremifene (selective estrogen
receptor modulator) decreased signiﬁcantly levels of bone
resorption and bone formation markers [37–39].
5.3. Treatment with Bone Formation-Stimulating Agents.
Recombinant human parathyroid hormone (1–34) (rhPTH-
(1–34)) induced a rapid increase in serum concentrations
of bone formation markers, especially P1NP, followed by
an increase in bone resorption marker levels [40, 41]. After
6 to 9 months of treatment, BTM attained the maximum
(50 to 250% above baseline), then slightly decreased, but
remained elevated. By contrast, during combined treatment
(alendronate and rhPTH-(1–34)) started 6 months after the
beginning of the anti-resorptive treatment, BTM levels were
lower and the increase in aBMD at the spine and femoral
neck was smaller than after rhPTH-(1–34) alone [41].
6. Summary,Conclusions, andPerspectives
Overall, in older men, higher BTM levels are associated with
lower aBMD and faster bone loss. Thus, in older men, accel-
erated bone turnover is probably a major determinant of
bone loss and osteoporosis. There are two major directions
for the further studies on BTM in men. From the scientiﬁc
point of view, development of markers reﬂecting qualitative
properties of bone would improve our understanding of the
mechanisms of bone fragility in older men. From the practi-
cal point of view, BTMs do not improve the identiﬁcation of
men at high risk of accelerated bone loss or fragility fracture.
In older men, changes in BTM levels induced by anti-
osteoporotic treatment are similar to those found in post-
menopausal women. However, we need more studies on the
association between changes in bone turnover rate and the
decreaseintheriskoffragilityfracture.Inparticular,weneed
studies on the utility of BTM measurement for the improve-
ment of the persistence and adherence to the anti-osteopo-
rotic treatment in men.4 Journal of Osteoporosis
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